Louis G. Lange - 01 Jun 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role: Director
Signature: /s/ Louise Kooij by Power of Attorney from Louis G. Lange
Issuer symbol: NAMS
Transactions as of: 01 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:59:38 UTC
Previous filing: 02 May 2025
Next filing: 09 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LANGE LOUIS G	Director	C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS	/s/ Louise Kooij by Power of Attorney from Louis G. Lange	03 Jun 2025	0001238401

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NAMS	Ordinary Shares	Options Exercise	$0	+68	+0.24%	$0.000000	28,186	01 Jun 2025	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NAMS	Restricted Stock Unit	Options Exercise		-68	-100%		0	01 Jun 2025	Ordinary Shares	68		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.
F2	Each RSU represents a contingent right to receive one ordinary share.
F3	3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025.
F4	The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.